Cerus Stock

Cerus EBIT

The EBIT of Cerus (CERS) as of Jul 27, 2026 is -36.35 M USD. In the previous year, EBIT was -11.88 M USD — a change of 205.97% (lower).

EBIT

-36.35 MUSD

YoY

205.97%

Last updated:

In 2026, Cerus's EBIT was -36.35 M USD, a 205.97% increase from the -11.88 M USD EBIT recorded in the previous year.

The Cerus EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (M USD)
Date
EBIT (M USD)
Jan 1, 2020
-58.33 base
Jan 1, 2021
-49.13 base
Jan 1, 2022
-36.51 base
Jan 1, 2023
-29.47 base
Jan 1, 2024
-11.88 base
Jan 1, 2025
-36.35 base
Jan 1, 2026 (e)
-1.92 base
Jan 1, 2027 (e)
5.60 base
YEAREBIT (M USD)
2027 est 5.60
2026 est -1.92
2025 -36.35
2024 -11.88
2023 -29.47
2022 -36.51
2021 -49.13
2020 -58.33
2019 -66.23
2018 -54.99
2017 -57.53
2016 -60.29
2015 -61.08
2014 -44.35
2013 -28.30
2012 -17.30
2011 -15.92
2010 -15.96
2009 -23.83
2008 -30.53
2007 -43.17
2006 -9.48
Access this data via the Eulerpool API

Cerus Revenue

Cerus Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2020
91.92 M USD
-58.33 M USD
-59.86 M USD
Jan 1, 2021
130.86 M USD
-49.13 M USD
-54.38 M USD
Jan 1, 2022
162.05 M USD
-36.51 M USD
-42.83 M USD
Jan 1, 2023
156.37 M USD
-29.47 M USD
-37.49 M USD
Jan 1, 2024
180.27 M USD
-11.88 M USD
-20.92 M USD
Jan 1, 2025
206.13 M USD
-36.35 M USD
-15.63 M USD
Jan 1, 2026 (e)
238.12 M USD
-1.92 M USD
-5.76 M USD
Jan 1, 2027 (e)
259.83 M USD
5.60 M USD
0.00 USD

Cerus Margins

Cerus stock margins

The Cerus margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Cerus. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Cerus.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
55.23 %
-63.46 %
-65.12 %
Jan 1, 2021
51.49 %
-37.55 %
-41.55 %
Jan 1, 2022
53.75 %
-22.53 %
-26.43 %
Jan 1, 2023
55.25 %
-18.85 %
-23.98 %
Jan 1, 2024
55.21 %
-6.59 %
-11.60 %
Jan 1, 2025
53.50 %
-17.63 %
-7.58 %
Jan 1, 2026 (e)
53.50 %
-0.81 %
-2.42 %
Jan 1, 2027 (e)
53.50 %
2.15 %
0.00 %

Cerus Stock analysis

What does Cerus do? Cerus Corporation is a biotechnology company specialized in the development and marketing of products for the processing and transfusion of blood products. The company was founded in 1991 and is headquartered in Concord, California. Cerus Corporation is listed on the NASDAQ stock exchange and employs approximately 450 employees worldwide. The history of Cerus Corporation began when its founder, Stephen Isaacs, received a blood transfusion and subsequently became infected with the Hepatitis B virus. This incident inspired him to start a company focusing on the development of technologies for the safe transfusion of blood products. In 1993, Cerus Corporation introduced its first product, the Intercept Blood System. This system utilized ultraviolet light and chemicals to deactivate pathogens such as viruses, bacteria, and parasites in blood. The business model of Cerus Corporation revolves around the development and distribution of products for medical needs. The company's focus is on the processing of blood products such as platelets, plasma, and red blood cells to reduce the risk of infectious diseases and other potentially harmful side effects in blood transfusions. Cerus also provides training and technical support for its products. Cerus Corporation has several divisions, including the Intercept Blood System, Blood Center Technology, and Innovative Technology. The Intercept Blood System division is the largest and most popular, offering products such as the Intercept Blood System for platelets and plasma, the Intercept Blood System for red blood cells, the Intercept Blood System for PAS (reduced volume blood bank) and the Intercept Blood System for Fresh Frozen Plasma. Cerus Corporation's Blood Center Technology division provides technologies and devices for blood banks and transfusion services, including transfusion safety systems and blood testing devices. The Innovative Technology division specializes in the development of new technologies and products. Another product of Cerus Corporation is INTERCEPT FDA Approved Plasma, which was approved by the US Food and Drug Administration (FDA) in 2018. The plasma is made from donated blood and processed using the INTERCEPT technology. The INTERCEPT technology decontaminates various blood components, increasing their safety in transfusions. Cerus Corporation has achieved significant success in the medical technology industry. Cerus Corporation's Intercept Blood System is approved in more than 25 countries and has helped save countless lives and prevent diseases for healthcare professionals and patients. The company has been recognized multiple times for its innovative products and services, including receiving the Gold Medal at the Edison Awards in 2017 and the Technology Pioneer Award from the World Economic Forum in 2016. In summary, Cerus Corporation is a successful biotechnology company that develops and distributes innovative technologies for the processing and transfusion of blood products. Through its technology and products, Cerus contributes to increasing the safety of blood transfusions by reducing the risk of infectious diseases and other potentially dangerous side effects. Cerus Corporation will continue to play an important role in the medical technology industry in the future. Cerus is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Cerus's EBIT

Cerus's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Cerus's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Cerus's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Cerus’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Cerus stock

EBIT of Cerus is -36.35 M USD in 2026.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Cerus

All Key Metrics — Cerus